Bob Duggan's Latest Bet: Summit Therapeutics Surges 1,000% on Groundbreaking Lung Cancer Drug Results

Bob Duggan, the billionaire investor and former CEO of Pharmacyclics, has made another major splash in the biotech world with his latest investment, Summit Therapeutics (NASDAQ: SMMT). The company’s stock has rocketed more than 1,000% in just the past year, making it one of the hottest bets in the biotechnology sector. The driving force behind this meteoric rise is promising data from a late-stage clinical trial, which revealed that Summit’s experimental cancer drug, Ivonescimab, outperformed Merck’s highly successful blockbuster Keytruda in patients with a form of non-small cell lung cancer (NSCLC).

Want to read more?

Subscribe to doctorsinbusinessjournal.com to keep reading this exclusive post.

Subscribe Now